Amicus Therapeutics Reports Positive Preliminary Results For AT2220

AMICUS To Present At Needham Healthcare Conference ; Webcast At 5:00 PM

Correction: Amicus Loss Widen

Amicus Therapeutics Q4 Loss Narrows - Quick Facts

Amicus Therapeutics Q4 12 Earnings Conference Call At 5:00 PM ET

Trade FOLD now with

6/26/2012 4:30 PM ET

Amicus Therapeutics (FOLD: Quote) said Monday that preliminary results from an ongoing Phase 2 open-label drug-drug interaction study to evaluate AT2220 was positive.

The study was conducted to evaluate the safety and pharmacokinetic effects of pharmacological chaperone AT2220 co-administered with enzyme replacement therapy for Pompe disease.

John Crowley, chairman and chief executive officer of the company, said, "It is a great step forward in the development of this Amicus platform technology in Pompe disease and we look forward to additional important data from the remaining two cohorts in this clinical study."

Click here to receive FREE breaking news email alerts for AMICUS THERAPEUTICS INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 133 Articles

Editors Pick

Gap Profit Climbs 43%

Gap Inc. Thursday after the markets closed that its first quarter profit rose 43% from last year, helped by higher sales and improved margins. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company eaffirmed its fiscal year 2013 earnings outlook, which is below analysts' current consensus estimate.

Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary

After moving sharply lower at the start of trading on Thursday, stocks showed a substantial recovery attempt over the course of the trading day. The rebound came as upbeat housing data helped offset worries about the Federal Reserve. The major averages climbed well off their worst levels of the day but still ended the session in the red.

Obama Outlines Counterterrorism Policy To Confront Shifting Threats

President Barack Obama delivered a highly-anticipated speech on his administration's evolving counterterrorism policies on Thursday, suggesting that the U.S. needs to move away from a "boundless global war on terror." More than a decade after the 9/11 attacks, Obama argued that the terrorist threat has shifted and evolved.